Literature DB >> 22447803

Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong.

C K Tung1, T P Chiang, M Lam.   

Abstract

Synthetic cannabinoids are hybrid herbal/chemical products which mimic the effects of cannabis. They are usually marketed as incense or 'herbal smoking blend', and best known by the brand names 'K2' and 'Spice'. Their popularity among recreational drug abusers has grown rapidly due to their easy availability, relatively low cost, non-detection by conventional drug tests, and ease of concealing their use from family and authorities. They took Europe and later North America by storm in the late 2000s, yet limited medical literature exists detailing their adverse effects. They began to emerge in the Hong Kong drug scene in 2009. We report on a man who developed acute mental disturbance after 4 weeks of daily K2 abuse. This is the first case report of mental disorder caused by synthetic cannabinoid abuse in a Chinese.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447803

Source DB:  PubMed          Journal:  East Asian Arch Psychiatry        ISSN: 2078-9947


  10 in total

Review 1.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

Review 2.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

Review 3.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

Review 4.  Spicing things up: synthetic cannabinoids.

Authors:  Max Spaderna; Peter H Addy; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

5.  Driving under the influence of synthetic cannabinoids ("Spice"): a case series.

Authors:  Frank Musshoff; Burkhard Madea; Gerhard Kernbach-Wighton; Wolfgang Bicker; Stefan Kneisel; Melanie Hutter; Volker Auwärter
Journal:  Int J Legal Med       Date:  2013-05-01       Impact factor: 2.686

Review 6.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

7.  First-Episode of Synthetic Cannabinoid-Induced Psychosis in a Young Adult, Successfully Managed with Hospitalization and Risperidone.

Authors:  Aaron J Roberto; Aileen Lorenzo; Kevin J Li; Jonathan Young; Abhishek Mohan; Subhash Pinnaka; Kyle A B Lapidus
Journal:  Case Rep Psychiatry       Date:  2016-06-26

8.  Health and Social Problems Associated with Recent Novel Psychoactive Substance (NPS) Use Amongst Marginalised, Nightlife and Online Users in Six European Countries.

Authors:  Marie Claire Van Hout; Annemieke Benschop; Michal Bujalski; Katarzyna Dąbrowska; Zsolt Demetrovics; Katalin Felvinczi; Evelyn Hearne; Susana Henriques; Zsuzsa Kaló; Gerrit Kamphausen; Dirk Korf; Joana Paula Silva; Łukasz Wieczorek; Bernd Werse
Journal:  Int J Ment Health Addict       Date:  2017-12-07       Impact factor: 3.836

9.  Epidemics of HIV, HCV and syphilis infection among synthetic drugs only users, heroin-only users and poly-drug users in Southwest China.

Authors:  Shu Su; Limin Mao; Jinxian Zhao; Liang Chen; Jun Jing; Feng Cheng; Lei Zhang
Journal:  Sci Rep       Date:  2018-04-26       Impact factor: 4.379

Review 10.  Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems.

Authors:  William E Fantegrossi; Catheryn D Wilson; Michael D Berquist
Journal:  Drug Metab Rev       Date:  2018-01-31       Impact factor: 4.518

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.